Examorelin · Growth Hormone Releasing Hexapeptide
A synthetic hexapeptide growth hormone secretagogue and one of the most potent GHRPs available. Hexarelin produces a significantly stronger GH pulse than Ipamorelin and has unique cardioprotective properties through direct cardiac GHS receptor activation — independent of its GH-releasing effects.
Hexarelin (examorelin) is a synthetic hexapeptide that acts as a potent agonist of the ghrelin receptor (GHS-R1a), producing robust growth hormone release from the pituitary. It belongs to the same GHRP family as Ipamorelin but is significantly more potent — producing a larger GH pulse at equivalent doses. Unlike Ipamorelin, Hexarelin does elevate cortisol and prolactin to a moderate degree, which limits its suitability for extended continuous use.
Hexarelin's most distinctive property is its direct action on GHS receptors in cardiac tissue — independent of its pituitary GH-releasing effects. Research has demonstrated that Hexarelin protects cardiac tissue from ischemia-reperfusion injury, improves cardiac function in heart failure models, and promotes cardiac recovery through mechanisms that operate even in hypophysectomised (pituitary-removed) animals. This cardiac-specific action has generated significant research interest for post-cardiac event recovery.
Hexarelin produces one of the strongest GH pulses of any GHRP — significantly greater than Ipamorelin and comparable to GHRP-2. However, unlike GHRP-2, Hexarelin shows significant desensitisation with continuous use — GH response diminishes with repeated daily administration. Intermittent protocols (3-4x per week rather than daily) are generally recommended to maintain GH responsiveness.
For most general GH optimisation purposes, Ipamorelin's cleaner profile (no cortisol elevation, no desensitisation) makes it preferable for extended use. Hexarelin is most relevant for short-term intensive GH protocols, cardiac recovery applications, or situations where maximum GH pulse amplitude is the priority and extended use is not planned.